检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Wojciech Jurczak,Nagah Elmusharaf,Christopher P Fox,William Townsend,Amanda G Paulovich,Jeffrey R Whiteaker,Fanny Krantz,Chuan-Chuan Wun,Graeme Parr,Shringi Sharma,Veerendra Munugalavadla,Richa Manwani,Emma Dean,Talha Munir

Therapeutic advances in hematology（2023）

引用 0|浏览21
暂无评分
摘要
NCT03328273.
更多
查看译文
关键词
relapsed/refractory chronic lymphocytic leukemia,ceralasertib,acalabrutinib,monotherapy,high-risk
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要